echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > CD19 Targets New Fc Optimized Immune Enhancement Monoantid Tafasitamab To Apply for Listing in the U.S.

    CD19 Targets New Fc Optimized Immune Enhancement Monoantid Tafasitamab To Apply for Listing in the U.S.

    • Last Update: 2020-06-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Recently, MorphoSys announced that it had filed a patentasitamab (MOR208) biologics licensing application (BLA) with the U.SFood and Drug Administration (FDA) to treat patients with recurrent or refractive diffuse large B-cell lymphoma (r/r DLBCL)Tafasitamab is a new type of human-derived Fc domain optimized immune-enhanced monoclonal antibody, CD19 is a clear biomarker of a variety of B-cell malignanciesfda has a 60-day filing review period to determine whether the BLA is complete and acceptedDr Malte Peters, Chief Development Officer of MorphoSys, said: "This BLA submission marks an important milestone in MorphoSys' history and demonstrates our commitment to addressing the high medical needs of recurrent or refractive DLBCLIf approved, the tafasitamab-to-nadoamine programme will be an alternative treatment option for the group of patients with this serious disease"
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.